Integrative multi-omics and experimental validation reveal the oncogenic role of DDX52 in liver hepatocellular carcinoma.
Integrative analyses and experimental validation suggest that DDX52 is a potential prognostic biomarker and therapeutic target in LIHC and its associations with immune features and multiple cancer-related pathways provide hypotheses for future mechanistic investigation.